Login to Your Account

OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M

By Aaron Lorenzo

Monday, June 21, 2004
OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription